A5045640368- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Glycosylation and Glycoproteins Research
- Advanced Biosensing Techniques and Applications
- Medical Imaging and Pathology Studies
- MicroRNA in disease regulation
- Cancer Mechanisms and Therapy
- Epigenetics and DNA Methylation
Xiangya Hospital Central South University
2013
Central South University
2013
Abstract Background: Early diagnosis is critical to lung adenocarcinoma patients’ survival but faces inadequacies in convenient early detection. Methods: We applied a comprehensive microarray of 130,000 peptides detect “autoantibody signature” that autoantibodies binding mimotopes for detection stage 0–I LUAD. Plasma samples were collected from 147 early-stage (Early-LUAD), 108 benign disease (BLD), and 122 normal healthy controls (NHC). Clinical characteristics, low-dose CT (LDCT),...
<p>Corresponding abbreviated number for differential peptides probes in correlation plot.</p>
<p>Random forest model and GO enrichment. a, Schematic plot of random forest; b, terms enriched by the matched proteins differential peptide probes.</p>
<p>Figure S4. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus BLD. Each boxplot represents an individual peptide signature the two sample sets.</p>
<p>Reproducibility of peptides microarray. a, Heatmap spearman correlation 47 samples tested with 3 technical repeats within one batch. b. 6 repeatedly across batches.</p>
<p>Corresponding signal of previous reported autoantibodies for early lung cancer detection were evaluated in our study cohort with both HuProtTM protein microarray (detail data not shown) and peptide array. All peptides aligned to 10 proteins using blastp method, 246 mapped under the set e-value 1 identity 90. Accumulated was as autoantibody corresponding antigen protein. Nine had effective testing value HuprotTM. a.t test P signals Early-LUAD versus NHC from array respectively. Two 2...
<p>Figure S5. Correlation between differential autoantibody signatures from Early-LUAD versus BLD and blood routine test. Some of the 143 positively correlated with RDW.CV.</p>
<div>AbstractBackground:<p>Early diagnosis is critical to lung adenocarcinoma patients’ survival but faces inadequacies in convenient early detection.</p>Methods:<p>We applied a comprehensive microarray of 130,000 peptides detect “autoantibody signature” that autoantibodies binding mimotopes for detection stage 0–I LUAD. Plasma samples were collected from 147 early-stage (Early-LUAD), 108 benign disease (BLD), and 122 normal healthy controls (NHC). Clinical...
<div>AbstractBackground:<p>Early diagnosis is critical to lung adenocarcinoma patients’ survival but faces inadequacies in convenient early detection.</p>Methods:<p>We applied a comprehensive microarray of 130,000 peptides detect “autoantibody signature” that autoantibodies binding mimotopes for detection stage 0–I LUAD. Plasma samples were collected from 147 early-stage (Early-LUAD), 108 benign disease (BLD), and 122 normal healthy controls (NHC). Clinical...
<p>Random forest model and GO enrichment. a, Schematic plot of random forest; b, terms enriched by the matched proteins differential peptide probes.</p>
<p>Corresponding abbreviated number for differential peptides probes in correlation plot.</p>
<p>Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.</p>
<p>Figure S4. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus BLD. Each boxplot represents an individual peptide signature the two sample sets.</p>
<p>Reproducibility of peptides microarray. a, Heatmap spearman correlation 47 samples tested with 3 technical repeats within one batch. b. 6 repeatedly across batches.</p>
<p>Figure S3. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus NHC. Each boxplot represents an individual peptide signature the two sample sets.</p>
<p>Corresponding signal of previous reported autoantibodies for early lung cancer detection were evaluated in our study cohort with both HuProtTM protein microarray (detail data not shown) and peptide array. All peptides aligned to 10 proteins using blastp method, 246 mapped under the set e-value 1 identity 90. Accumulated was as autoantibody corresponding antigen protein. Nine had effective testing value HuprotTM. a.t test P signals Early-LUAD versus NHC from array respectively. Two 2...
<p>Figure S3. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus NHC. Each boxplot represents an individual peptide signature the two sample sets.</p>
<p>Figure S5. Correlation between differential autoantibody signatures from Early-LUAD versus BLD and blood routine test. Some of the 143 positively correlated with RDW.CV.</p>
<p>Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.</p>
<p>Corresponding abbreviated number for differential peptides probes in correlation plot.</p>
<p>Random forest model and GO enrichment. a, Schematic plot of random forest; b, terms enriched by the matched proteins differential peptide probes.</p>
<p>Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.</p>
<p>Figure S5. Correlation between differential autoantibody signatures from Early-LUAD versus BLD and blood routine test. Some of the 143 positively correlated with RDW.CV.</p>
<p>Corresponding abbreviated number for differential peptides probes in correlation plot.</p>